The detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–specific
antibodies in the serum of an individual indicates previous infection or vaccination …

A robust serological test to detect neutralizing antibodies to SARS-CoV-2 is urgently needed
to determine not only the infection rate, herd immunity and predicted humoral protection, but …

Small number of SARS-CoV-2 epidemic lineages did not efficiently exhibit a neutralization
profile, while single amino acid mutation in the spike protein has not been confirmed in …

Most of the patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) mount a humoral immune response to the virus within a few weeks of infection, but …

One year in the coronavirus disease 2019 (COVID-19) pandemic, the first vaccines are
being rolled out under emergency use authorizations. It is of great concern that newly …

Administration of convalescent plasma or neutralizing monoclonal antibodies (mAbs) is a
potent therapeutic option for coronavirus disease 2019 (COVID-19) caused by severe acute …

The emergence of SARS-CoV-2 variants with mutations in the spike protein is raising
concerns about the efficacy of infection-or vaccine-induced antibodies. We compared …

Both the SARS-CoV-2 pandemic and emergence of variants of concern have highlighted the
need for functional antibody assays to monitor the humoral response over time. Antibodies …

Neutralizing antibodies targeting the receptor-binding domain (RBD) of the SARS-CoV-2
spike (S) block severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) entry into …

Coronaviruses are enveloped, positive-stranded RNA viruses that contain the largest known
RNA genomes to date. As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …